Circio Holding Asa · OSL:CRNA

Circio Holding Asa — SITC 2022 Annual Meeting (Society for Immunotherapy of Cancer)

12 slides from Circio Holding Asa's conference presentation, Nov 10, 2022

  1. Slide 1: SITC 2022 Annual Meeting, November 8-12, Massachusetts

    20322 NOVEMBER 8-12 MASSACHUSETTS r he Society for Immuno erapy of Cancer © - am Annual Meeting nd Pre-Conference Progra ms THE LEADING CANCER IMMUNOTHERAPY AND TUMOR IMMUNOLOGY CONFERENCE “#511022

  2. Slide 2: Repeat dosing of oncolytic adenovirus ONCOS-102 in anti-PD-1 resistant melanoma

    Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti- PD-1 resistant melanoma A. Shoushtari1,2, A. J. Olszanski3, M. Nyakas4, T. J. Hornyak5, J. D. Wolchok1,2,6,7, V. Levitsky8, T. B. Hansen8, and L. Ottese

  3. Slide 3: ONCOS-102 is an engineered oncolytic immunotherapy based on an Adenovirus serotype 5 backbone

    ONCOS-102 is an engineered oncolytic immunotherapy based on an Adenovirus serotype 5 backbone Drives inflammatory response to reverse immuno-suppressive defence mechanisms in the tumor Primes tumor-antigen specific T-cell responses Delivers GM-CSF as an immune stimulatory payload

  4. Slide 4: Two intra-tumoral ONCOS-102 dosing regimens were tested in 21 PD-1 resistant melanoma patients

    Two intra-tumoral ONCOS-102 dosing regimens were tested in 21 PD-1 resistant melanoma patients Part 1 Day BL 1 2 3 6 9 12 15 18 21 24 27 -3 to-1 Weeks (n=9) CPO ONCOS-102 pembrolizumab Part 2 Day BL 1 2 3 6 9 12 15 18 21 24 27 Weeks (n=12) -3 to-1 Imaging CPO ONCOS-102 ONCOS-102 + pembrolizumab Biop

  5. Slide 5: Patient characteristics: higher tumor burden and more stage IV disease in Part 2 patients

    Patient characteristics: higher tumor burden and more stage IV disease in Part 2 patients Part 1 Part 2 Total Part 1 Part 2 Total (n=9) (n=12) (N=21) (n=9) (n=12) (N=21) Median age, years (range) 73 (40–87) 72 (43–83) 73 (40–87) Prior cancer therapy, n (%) Sex (female/male), n 4/5 6/6 10/11 Surgery

  6. Slide 6: Both regimens were well-tolerated with similar safety profiles and no dose limiting toxicities observed

    Both regimens were well-tolerated with similar safety profiles and no dose limiting toxicities observed Treatment related adverse events (≥1 patient) AEs relateda to ONCOS-102, only AEs relateda to ONCOS-102 and Preferred term pembrolizumab n (%) Part 1 Part 2 Total Part 1 Part 2 Total (N=9) (N=12)

  7. Slide 7: Part 2 regimen supports prolonged ONCOS-102 tumor exposure which correlated with disease control

    Part 2 regimen supports prolonged ONCOS-102 tumor exposure which correlated with disease control ONCOS-102 viral particles (VP) in tumor, qPCR on tumor biopsy DNA Part 1 vs. Part 2 patients Patients w/DCR vs. PD o ONCOS-102 replication supported in tumors for at least 6 injections and until week 9 o

  8. Slide 8: An overall ORR of 35% was observed with similar response rates in Part 1 and Part 2

    An overall ORR of 35% was observed with similar response rates in Part 1 and Part 2 Best response in target lesions (BOR), tumor burden change from baseline (%) Part 1; n=8 Part 2; n=12 ORR=37.5% ORR=33.3% (3/8) (4/12)

  9. Slide 9: Systemic activity was more pronounced with Part 2 concomitant dosing regimen

    Systemic activity was more pronounced with part 2 concomitant dosing regimen Response in individual tumors % change from baseline; injected and non-injected target lesions (n=16)1 (n=36) Observed systemic effect: o 12 of 36 (33%) non-injected target lesions reduced in size o 8 of 15 (53%) patients h

  10. Slide 10: Robust increase in T-cell infiltration in both Part 1 and 2, persisting at week 9

    Robust increase in T-cell infiltration in both Part 1 and 2, persisting at week 9 in patients with clinical benefit CD8+ T-cell tumor infiltration CD8+ T-cell infiltration, aggregated Tumor biopsy IHC, patient case example Average level in biopsies per group p = 0.01 Progression on 3x ONCOS-102 only

  11. Slide 11: Gene expression revealed specific up-regulation of immune related pathways in Part 2

    Gene expression revealed specific up-regulation of immune related pathways in Part 2 Gene expression profile, total RNAseq on tumor biopsies Changes at week 9 vs. baseline; Part 1 vs. Part 2 Gene ontologies Categories of differentially expressed genes in Part 2 Specifically upregulated in Part 2

  12. Slide 12: Part 2 concomitant dosing regimen selected for Phase 2 development of ONCOS-102

    Part 2 concomitant dosing regimen selected for Phase 2 development of ONCOS-102 in PD-1 resistant melanoma Summary & conclusions • Both ONCOS-102 dosing regimens were safe and well-tolerated in combination with pembrolizumab • 35% ORR was observed, with similar response rates in Part 1 and Part 2 •

Circio Holding — SITC 2022 Annual Meeting (Society for Immunotherapy of Cancer) on 6ix